Navigation Links
Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results
Date:2/4/2009

endence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Additional Important Information

This press release is for informational purposes only and does not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell securities of the Company. The tender offer is being made pursuant to a tender offer statement on Schedule TO (including the offer to purchase, letter of transmittal and other related tender offer materials, w
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
2. Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
3. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
4. Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status
5. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
6. Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
7. Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008
8. Indevus Pharmaceuticals To Present at RBC Capital Markets Conference
9. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
10. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
11. Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Pittsburgh, PA (PRWEB) October 20, 2014 ... new, minimally-invasive procedure that enables physicians to repair a ... , The MitraClip system, developed by ... regurgitation (MR), a progressive and life-threatening condition in which ... allowing blood to flow backward from the heart’s left ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 Women’s ... Specialists in Obstetrics & Gynecology of Columbus, Inc., A ... women’s healthcare services to more than 100,000 patients annually. ... though all ages and stages of a women’s life. ... office locations in Westerville and Dublin. , Dr. ...
(Date:10/20/2014)... 20, 2014 Zereana Jess-Huff, a 34-year-old mother, ... 2014 on a platform to think outside the bra. She ... her position to raise awareness about women’s other lady parts. ... cancer. You say the color pink and everybody knows what ... a fact that it has not been won when it ...
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... Rockynol Retirement Community broke ground on ... $11 million project will include the latest in Assisted ... full-service restaurant style dining. , “We are excited to ... Living apartments,” said Kara Hanzie, Rockynol Executive Director during ... care and this investment is proof of our commitment.” ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2
... a national leader in accounts receivable management, and collection services to ... created position of Chief Operating Officer (COO). , ... ... leader, MDS ( www.meddatsys.com ), has announced Eugene (Gene) Schneider to ...
... cause irreversible damage, doctors say , , WEDNESDAY, March 18 (HealthDay ... death Wednesday of actress Natasha Richardson, reports that she suffered ... Canadian ski slope on Tuesday have many people wondering how ... of the most lauded acting families in Great Britain; her ...
... "The White House made the correct decision ... Veterans Affairs to have military veterans, personal insurance ... said VAdm. Norb Ryan, Jr., USN-Ret., president of ... said he advised President Obama that "pursuing this ...
... cents donated for every person that playsPHOENIX, March 18 ... home products, is kicking off The Candle Game to benefit ... the free online game, Gold Canyon will donate 10 cents ... Game can be played online at http://thecandlegame.com and ...
... was 98% for Kit-positive GIST patients taking Gleevec vs. ... patients experienced recurrence of GIST(2) within a median of ... treatment in the US and Switzerland indicated to reduce ... is underway in the EU(4) EAST HANOVER, N.J., March ...
... March 18 Speaker Nancy Pelosi announced this afternoon ... that could have forced veterans to use their private insurance ... Pelosi made the announcement at a meeting she and House ... veterans, service organizations, who greeted the news with a standing ...
Cached Medicine News:Health News:Medical Data Systems, Inc. (MDS) Announces New Chief Operating Officer (COO) 2Health News:Medical Data Systems, Inc. (MDS) Announces New Chief Operating Officer (COO) 3Health News:Brain Hemorrhage Might Explain Natasha Richardson's Death 2Health News:Brain Hemorrhage Might Explain Natasha Richardson's Death 3Health News:White House Makes Correct Decision On Veterans Insurance Proposal 2Health News:Gold Canyon Ignites Hope With Online Charity Candle Game 2Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 2Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 3Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 4Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 5Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 6Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 7Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 8Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 9Health News:Pelosi: Administration Will Not Force Veterans to Use Private Insurance to Pay for Treatment of Combat-Related Injuries 2
(Date:10/17/2014)... N.C. , Oct. 17, 2014 ... the Medical Affairs function has come across several ... resources efficiently and managing globalization.  ... Practices, LLC is dedicated to providing benchmarking and ... Medical Affairs Consortium is a service composed of ...
(Date:10/17/2014)... Oct. 17, 2014  Hanger, Inc. (NYSE: ... its results of operations for the quarter ended September ... market closes.  A conference call to discuss these results ... Friday, November 7, 2014. Those wishing to participate should ... November 14, 2014 by dialing 1-855-859-2056 and referencing Conference ...
(Date:10/17/2014)... UBM Medica US announces that Neurology Times ... for neurologists and other healthcare providers, features special coverage on ... discussions of the latest developments in approaches to diagnosis. ... , more than the total of those who have multiple ... can be difficult because there are no confirmatory medical tests. ...
Breaking Medicine Technology:Early Key Findings from the Medical Affairs Consortium Research 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... Repligen Corporation,(Nasdaq: RGEN ) announced today that ... to evaluate the use of RG1068, synthetic human ... by magnetic resonance,imaging (MRI). This Phase 3 study ... approximately 250 patients will receive an,unenhanced MRI followed ...
... First-in-Class Treatment for Type 2 Diabetes -, ... company focused on the discovery and development of,proprietary ... today that it has dosed the first cohort ... of MBX-2982, a potential first-in-class treatment,for type 2 ...
Cached Medicine Technology:Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 2Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 3Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 4Metabolex Initiates Phase 1 Trial of MBX-2982 2
Allows for custom orientation of specimen...
Honing compound for knife sharpening, 6 grams net...
Standard knife with box, C profile...
... sectioning work, it is necessary to cool a ... can be fitted to most microtomes and will ... lower, depending on conditions. The equipment consists of ... cooling stage is best suited for operation with ...
Medicine Products: